



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/038251
- (22) **International Filing Date:**
21 June 2021 (21.06.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/042,299 22 June 2020 (22.06.2020) US
63/122,877 08 December 2020 (08.12.2020) US
- (71) **Applicant: NGM BIOPHARMACEUTICALS, INC.**
[US/US]; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).
- (72) **Inventors: CRAWLEY, Suzanne Christine;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **FAN, Bin;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **LI, Betty Chan;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **RIVERA, Lee Benjamin;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **SISSONS, James Robert;** 333 Oyster Point Boulevard,

South San Francisco, California 94080 (US). **SITRIN, Jonathan;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **WANG, Yan;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **ZHAO, Xuan;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).


- (74) **Agent: KOIPALLY, Joseph J.;** Fish & Richardson, P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) **Title: LAIR-1-BINDING AGENTS AND METHODS OF USE THEREOF**

Figure 1



(57) **Abstract:** The present disclosure provides binding agents, such as antibodies, that specifically bind LAIR-1, including human LAIR-1, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*